A phase I and pharmacokinetic (PK) study of continuous daily administration of P1446A-05, a potent and specific oral Cdk4 inhibitor.

被引：0
|
作者：
Hao, Desiree
Chu, Quincy
Welch, Stephen
Yau, Cindy Y. F.
Spratlin, Jennifer L.
Tang, Patricia
MacKenzie, Mary J.
Townsley, Carol A.
Arndt, Diane
Johnson, Laureen
Trapsa, Daniela
Degendorfer, Pamela
Kulkarni, Sujay
Jawlekar, Gajendra
Dhobe, Poornima
Oza, Amit M.
机构：
[1] Tom Baker Canc Clin, Calgary, AB, Canada
[2] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada
[3] London Reg Canc Program, London, ON, Canada
[4] Ozmosis Res Inc, Toronto, ON, Canada
[5] Piramal Healthcare Ltd, Bombay, Maharashtra, India
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3013
引用
收藏
页数：1
相关论文
共 17 条
  • [1] Phase I trial of the CDK 4/6 inhibitor, P1446A-05 (voruciclib) in combination with the BRAF inhibitor (BRAFi), vemurafenib in advanced, BRAF-mutant melanoma
    Diab, Adi
    Martin, Alison
    Simpson, Lauren
    Algazi, Alain Patrick
    Chawla, Purvi
    Kim, Dae Won
    Santra, Sourav
    Patel, Vruti
    Jadhav, Nitin
    Abhyankar, Dhiraj
    Davies, Michael A.
    Buch, Shama C.
    Kim, Kevin
    Daud, Adil
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [2] Phase I and pharmacokinetic study of BIBX 1382, an EGFR inhibitor, as continuous daily oral administration.
    Dittrich, C
    Bruntsch, U
    Borner, M
    Weigang, K
    Huisman, H
    Amelsberg, A
    Wanders, J
    Hanauske, A
    Fumoleau, P
    ANNALS OF ONCOLOGY, 2000, 11 : 133 - 133
  • [3] A phase I study of selective cyclin dependent kinase inhibitor P1446A-05 administered on an intermittent schedule in patients with advanced refractory tumors
    Gupta, Sudeep
    Jain, Minish Mahendra
    Maru, Anish
    Nag, Shona Milon
    Somani, Naresh
    Mehta, Ajay O.
    Kulkarni, Sujay
    Acharya, Shivani Anil
    Dhobe, Poornima
    Jadhav, Nitin
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [4] Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration
    Dittrich, C
    Greim, G
    Borner, M
    Weigang-Köhler, K
    Huisman, H
    Amelsberg, A
    Ehret, A
    Wanders, J
    Hanauske, A
    Fumoleau, P
    EUROPEAN JOURNAL OF CANCER, 2002, 38 (08) : 1072 - 1080
  • [5] A phase I study of XZP-3287, a novel oral CDK4/6 Inhibitor, administered on a continuous dosing schedule, in patients with advanced solid tumours
    Xu, B.
    Wang, J.
    Liu, X.
    Fang, J.
    Yao, Z.
    Wang, J.
    ANNALS OF ONCOLOGY, 2019, 30 : 123 - 123
  • [6] A phase I study of the oral administration of irinotecan in combination with the potent P-glycoprotein (P-gp) inhibitor HM30181A
    Jimeno, Antonio
    Opyrchal, Mateusz
    Diamond, Jennifer Robinson
    Fountzilas, Christos
    Corr, Bradley
    Bezi, Ildiko
    Wang, Hui
    Kwan, Rudolf
    Zhi, Jay
    Cutler, David
    Boland, Patrick McKay
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [7] A phase I study of palbociclib (PALBO) plus everolimus (EVE) and exemestane (EXE) in hormone-receptor positive (HR+)/HER2-metastatic breast cancer (MBC) after progression on a CDK4/6 inhibitor (CDK4/6i): safety, tolerability and pharmacokinetic (PK) analysis.
    Barroso-Sousa, Romualdo
    Guo, Hao
    Barry, William Thomas
    Ferreira, Arlindo R.
    Rees, Rebecca
    Winer, Eric P.
    Wagle, Nikhil
    Tolaney, Sara M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [8] A Phase I and pharmacokinetic (PK) trial of CYC202, a novel oral cyclin-dependent kinase (CDK) inhibitor, in patients with advanced solid tumors: Exploration of three administration schedules.
    Faivre, S
    Pierga, JY
    Delbaldo, C
    Laurence, V
    Vera, K
    Bekradda, M
    Armand, JP
    Gianella-Borradori, A
    Dieras, V
    Girre, V
    Raymond, E
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6107S - 6107S
  • [9] A first-in-human phase I/II study of BLU-222, a potent, selective CDK2 inhibitor in patients with CCNE1-amplified or CDK4/6 inhibitor-resistant advanced solid tumors
    Yap, T. A.
    Moore, K. N.
    Patel, M.
    Henick, B. S.
    Do, D.
    Iheanacho, A.
    Zhang, H.
    Roche, M.
    Newberry, K.
    Hsieh, A.
    Juric, D.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S765 - S765
  • [10] VELA: A first-in-human phase 1/2 study of BLU-222, a potent, selective cyclin-dependent kinase (CDK) 2 inhibitor in patients with cyclin E1 gene (CCNE1)-amplified or CDK4/6 inhibitor (CDK4/6i)-resistant advanced solid tumors
    Yap, Timothy
    Patel, Manish
    Henick, Brian
    Moore, Kathleen
    Leary, Alexandra
    Do, Doreen
    Chapman, Josh
    Zhang, Hui
    Roche, Maria
    Newberry, Kate
    Rinne, Mikael
    Juric, Dejan
    GYNECOLOGIC ONCOLOGY, 2023, 176 : S173 - S173
12